Pacific Edge, which is banking on successfully commercialising its Cxbladder urine testing product, widened its first-half loss as it ramps up spending to set up its business in the US.
The Dunedin-based company made a loss of $3.2 million, or 1.2 cents per share, in the six months ended September 30, from $1.7 million, or 0.9 cents, a year earlier, it says in a statement.
Revenue climbed 29% to $325,000, though just $11,000 of that came from external customers.
"The majority of this net loss is the investment in the company's setting up of business in the US, clinical trials, product development and intellectual property as it is expensed," it says.
"The company is investing significant funds in the set-up and running of the commercial laboratory and the development of the US strategy in this financial year."
The shares fell 2.2% to 44 cents, having surged 137% this year. That values the company at $122.7 million.
Pacific Edge hopes to successfully bring its urine sampling system to market, having won clinical confirmation the Cxbladder is at least as effective as other methods from the American Journal of Urology.
The local company says that could be worth up to $100 million in five years.
Last month, the company completed its US lab in Pennsylvania and is waiting on regulatory approval to use the building.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Spark points finger at rain, Chorus for broadband problems
- New tax a case of guilty until proven innocent?
- Political Week: Two important messages from Brexit for New Zealand
- Can Andrew Little win next year’s election for Labour? A reluctant assessment
- Dunne on the defensive after falling for hoax. Or did he?
Most listened to
- Business Week in Review with Grant Walker & Andrew Patterson
- New bright line tax will cause stress and add extra costs says Auckland accountant Leicester Gouwland
- Rob Hosking discusses the two Brexit lessons for New Zealand - one reassuring, one warning
- Commerce Commission chief lawyer David Blacktop on competition law changes he'd like to see
- ASB's Nick Tuffley on the latest 'astounding' housing credit figures